Roundups, one-time gifts and a company match fund America’s Warrior Partnership aid to Veterans

COVINGTON, Ga., October 22, 2026

PureTalk, the Veteran-led wireless company known for offering premium wireless service at a fraction of the cost of major carriers, today announced it has raised more than $1 million for America’s Warrior Partnership (AWP), a national nonprofit that connects Veterans and their families with supportive community resources and services to help improve and save Veterans’ lives. The total combines monthly roundups where customers round their bill up to the nearest dollar, one-time customer donations and company matching campaigns, including a recent PureTalk match of $250,000 during the company’s America250 campaign this summer. Every donated dollar goes to AWP and its programs

“Building a community network to recognize and support the unique needs of Veterans and their families is at the heart of the American’s Warrior Partnership mission,” said Jim Lorraine, president and CEO of America’s Warrior Partnership. “PureTalk takes that concept and puts it into action. We are grateful for PureTalk’s partnership and their leading a groundswell of meaningful community support among their customers to measurably improve the lives of Veterans and their loved ones.”

“My dad gets his care from the VA, so the Deeds Not Words initiative is personal,” said William Curry, Chief Strategy Officer at Telrite Holdings. “We have Veterans to thank for ensuring America’s way of life. We want to help ensure theirs.”

“Veterans need a hand up, not a handout,” said Clint Romesha, Medal of Honor recipient and AWP board member Emeritus. “Since 2023, PureTalk and America’s Warrior Partnership have been working to give Veterans the support they need; we’ve raised over $1 million in that effort,” he continued. “That’s the definition of Deeds Not Words, right there.”

Marine Corps Veteran David Bennett received mortgage assistance that kept his family in their home after his wife unexpectedly lost her job.

“Me and my family fell on some hard times, and we didn’t know if we’d be able to keep our home,” Bennett said.

Army Reserve Veteran Dale Dyer was recovering from a serious injury that kept him out of work when the family’s vehicle broke down. AWP and PureTalk covered the repair so he could return to work.

The support continues. New PureTalk customers can start a monthly round-up or make a one-time donation when they sign up for PureTalk wireless service, or existing customers can donate through their online account. Details are available at PureTalk.com/roundup.

About PureTalk

PureTalk, a subsidiary of Telrite Holdings, Inc., is a Veteran-led wireless provider that offers superior wireless plans backed by a dependable nationwide 5G network at a fraction of the cost of major carriers. With 100% U.S.-based operations, including customer service, PureTalk built its reputation on honesty, integrity, and delivering real value to its customers. PureTalk is committed to supporting hardworking Americans and the military members who serve our country. Together with its customers, PureTalk has contributed more than $1 million to America’s Warrior Partnership and helped eliminate $10 million in veteran debt. It supports K9s For Warriors, mikeroweWORKS Foundation, and other organizations that help Veterans and their families. For more information, visit PureTalk.com.

About America’s Warrior Partnership

America’s Warrior Partnership is a national 501(c)(3) nonprofit that connects Veterans, their families and caregivers with resources, services and partnerships in their own communities. AWP works through its community integration model, the AWP Network and research initiatives that include Operation Deep Dive, a multi-year study of Veteran suicide and other non-natural deaths. Learn more at americaswarriorpartnership.org.

Media Contact Details
Megan Hanson`
Avaans Media
Email: Send Email

RENO, NV, October 22, 2026

Sarcomatrix Therapeutics Corp., a Delaware corporation based in Reno, Nevada, today reminded prospective investors that its accredited investor round, conducted under Regulation D, Rule 506(c), is scheduled to close on October 31, 2026, the closing date the company announced on October 1, 2026. The round runs on the KoreInside platform, with KoreTransfer USA LLC acting as transfer agent. The closing date remains subject to earlier closing if the round is fully subscribed or to extension at the company’s discretion, and the company will announce any change to it.

Sarcomatrix is a preclinical-stage company, which means its treatments have not yet been tested in people.

Program Development Update

Since the round opened on July 24, 2026, the company has selected the sulfate salt form of S-969 for development, engaged specialist vendors for drug substance and drug product manufacturing, and expanded its Board of Directors with two independent directors, as announced on September 11, 2026.

The next major step toward human testing is contracting the provider for the two-species Good Laboratory Practice (GLP) toxicology studies that regulators require before a drug can be given to people. The company expects the work required to reach an application to begin human testing to take approximately 12 months from the date that contract is signed. These are plans, not guarantees, and drug development frequently takes longer than expected or fails outright.

Use of Offering Proceeds

As described in the offering materials, proceeds are intended for Investigational New Drug (IND)-enabling nonclinical work, including two-species GLP toxicology; chemistry, manufacturing, and controls (CMC) work on drug substance, drug product, and toxicology formulation; regulatory preparation for a pre-IND meeting and IND assembly; intellectual property prosecution and license compliance; and governance, audit readiness, and working capital. Allocation is at the discretion of the Board of Directors and may change. Proceeds of the round will not fund the company through regulatory approval of any product candidate.

About the Program

S-969 is an oral small molecule that targets a key kinase to upregulate alpha-7 beta-1 integrin (α7β1 integrin), strengthening the connection between muscle fibers and their surrounding support structure and supporting muscle repair. Because this approach does not depend on which genetic mutation a patient carries, it is designed to be relevant across the patient population rather than a single subgroup. S-969 is in preclinical development for Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). An Orphan Drug Designation application for S-969 is in preparation. LAM-111, the company’s second program, holds Orphan Drug Designation in both the United States and the European Union.

From the Company

“Investors who are completing their review should know where the round stands and when it is scheduled to close,” said David Craig, Co-Founder, President, and Chief Executive Officer. “Our focus is unchanged: contract the safety studies and move S-969 toward an application to begin testing in people. We will tell investors plainly if anything about the timing changes.”

How to Participate

This offering is open only to accredited investors, a category defined by the U.S. Securities and Exchange Commission based on income, net worth, or professional credentials. Under Rule 506(c), a company must take reasonable steps to confirm that status, and a self-declaration alone is insufficient. Verification is handled through the offering platform. Accredited investors can review the offering at www.sarcomatrix.com/investors or invest directly at www.sarcomatrix.com/invest. Full offering terms, subscription documents, and complete risk disclosures are provided on the platform once accredited status has been verified. Verification and subscription steps take time to complete, and investors considering participation should allow for that before the scheduled closing date.

About Sarcomatrix Therapeutics Corp.

Sarcomatrix Therapeutics Corp., a Delaware corporation headquartered in Reno, Nevada, is a preclinical-stage biotechnology company developing therapies for muscle-wasting diseases, beginning with Duchenne muscular dystrophy. Its lead candidate, S-969, is an oral small molecule that targets a key kinase to upregulate α7β1 integrin, the primary laminin-binding protein in skeletal and cardiac muscle. A spinout of the University of Nevada, Reno, the company holds the S-969 program under a co-exclusive, worldwide license through the Nevada Research and Innovation Corporation. Its second program, LAM-111, is in development for LAMA2-related congenital muscular dystrophy. Learn more at sarcomatrix.com.

Risk Statement

The Company is a preclinical-stage biopharmaceutical company. It has no approved products, has generated no revenue from product sales, and has not initiated clinical trials. Neither S-969 nor LAM-111 has been tested in humans, and the timeline to an application to begin human testing depends on contracting, manufacturing, regulatory review, and funding, any of which may take longer than planned. The Company will require substantial additional capital to advance its programs, and there is no assurance that such capital will be available on acceptable terms or at all. There is no public market for the Company’s securities, and none is expected to develop. Product candidates in preclinical development frequently fail to advance to or through clinical development. Additional risks are described in the offering materials, which prospective investors should read in full.

Offering Legend

Sarcomatrix Therapeutics Corp. is conducting an offering of securities pursuant to Rule 506(c) of Regulation D under the Securities Act of 1933, as amended. The offering is available exclusively to verified accredited investors as defined in Rule 501(a) of Regulation D. Prospective investors must complete accredited investor verification prior to participation. Securities offered are restricted securities and are subject to limitations on transfer and resale. Investment in early-stage private companies involves a high degree of risk, including the possible loss of the entire investment.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding the offering and its closing date, development plans, anticipated timelines, regulatory strategy, and potential therapeutic applications. Forward-looking statements are based on current expectations and are subject to significant risks and uncertainties. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law. The Company is not a reporting company under the Securities Exchange Act of 1934, and the statutory safe harbors for forward-looking statements are not available to it.

No Offer

This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offer is made solely by means of the offering materials made available to verified accredited investors through the Company’s investment platform.

Media Contact Details
Ray Jordan President, Investor Relations and Public Relations, Putnam Insights
Email: Send Email
Website: sarcomatrix.com

Lakewood, NJ, October 22, 2026

FlightCompensations has launched a managed claims service for passengers whose journeys have been affected by eligible flight disruptions, including delays, cancellations, overbooking and missed connections. The service brings claim submission, document management, airline correspondence and claim tracking together in a single online process.

FlightCompensations operates on a fixed-fee model. The company charges a processing fee of EUR 39 per passenger following a successful recovery. The fee is billed separately rather than deducted as a percentage of the amount recovered.

A Managed Process From Submission to Outcome

Passengers submit details of a disrupted journey through the FlightCompensations website or via WhatsApp. The company reviews the information provided, requests supporting documents such as a boarding pass or booking confirmation where required, and manages all correspondence with the airline on eligible claims.

Each customer has access to a personal online dashboard showing the progress of the claim, the documents on file and messages from the claims team. The service currently handles claims involving more than 150 airlines.

Flight Monitoring and FlightComp+ Membership

In addition to claims handling, FlightCompensations offers monitoring for upcoming trips. Travelers can register a flight in advance and receive an email notification if it is significantly delayed or cancelled, allowing them to submit a claim promptly.

For frequent travelers, the company offers FlightComp+, an annual membership priced at EUR 49. Membership covers the processing fee on eligible claims and includes priority handling and alerts for future flights.

Founder’s Perspective

FlightCompensations was founded by Jaacov Sonenblick, a travel-industry professional who established the service after experiencing a flight cancellation himself.

“Our aim is to make the claims process straightforward for passengers from the moment they submit their flight details,” said Jaacov Sonenblick, Founder of FlightCompensations. “We built the service around a clear fixed-fee structure and a digital process that lets customers follow their claim at every stage, while our team manages the work with the airline.”

About FlightCompensations

FlightCompensations is a managed flight claims service operated by The Upgrade Concierge LLC. The company assists passengers with eligible flight disruption claims through digital claim submission, document management, airline correspondence and claim tracking. FlightCompensations is based in Lakewood, New Jersey, United States.

Website: https://flightcompensations.com/

Media Contact Details
Jaacov Sonenblick
FlightCompensations
Email: Send Email
Phone: +17324408018
Website: flightcompensations.com